Seven Fleet Capital Management LP — 13F Holdings & Portfolio
CIK 2092021 · latest 13F-HR filed 2026-08-17
Seven Fleet Capital Management LP manages $605.9M in 13F-reported U.S. long-equity assets across 114 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CGON (16.88%), TNGX (8.99%), TNGX (6.80%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 24 new positions and exited 43; 50 existing positions rose in reported value and 16 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-17
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 65.1%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Jul 6, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| Lim, Rod, Seung-Hwan Control | LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP since Feb 2025 | 50–75% | Individual |
| Liu, Brian, Guan-Chyun Control | LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER since Feb 2025 | 25–50% | Individual |
| SEVEN FLEET CAPITAL MANAGEMENT GP LLC Control | GENERAL PARTNER since Feb 2025 | Less than 5% | Domestic Entity |
| Liu, Brian, Guan-Chyun Control Indirect owner via SEVEN FLEET CAPITAL MANAGEMENT GP LLC | MANAGING MEMBER since Feb 2025 | 75% or more | Individual |
Ownership & leadership changes · 1 filing with changes since Jun 30, 2026
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedLim, Rod, Seung-Hwan · title LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP / MEMBER OF SEVEN FLEET ADVISORS LLC → LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP
- ChangedLiu, Brian, Guan-Chyun · title LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER / MANAGING MEMBER OF SEVEN FLEET ADVISORS LLC → LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER; ownership 50–75% → 25–50%
- ListedLim, Rod, Seung-Hwan · LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP / MEMBER OF SEVEN FLEET ADVISORS LLC · 50–75% · control person
- ListedLiu, Brian, Guan-Chyun · MANAGING MEMBER · 75% or more · indirect via SEVEN FLEET CAPITAL MANAGEMENT GP LLC · control person
- ListedLiu, Brian, Guan-Chyun · LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP AND CHIEF COMPLIANCE OFFICER / MANAGING MEMBER OF SEVEN FLEET ADVISORS LLC · 50–75% · control person
- ListedSEVEN FLEET CAPITAL MANAGEMENT GP LLC · GENERAL PARTNER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- CG ONCOLOGY INC$128.9M +2513.8%
- TANGO THERAPEUTICS INC$85.2M +810.9%
- REVOLUTION MEDICINES INC$37.5M +476.9%
- PHARVARIS N V$21.9M +448.9%
- LIQUIDIA CORPORATION$13.4M +188.5%
Top Trims
- AGIOS PHARMACEUTICALS INC-$5.0M -70.2%
- VAXCYTE INC-$4.5M -71.8%
- COMPASS THERAPEUTICS INC-$2.2M -81.3%
- IDEAYA BIOSCIENCES INC-$1.5M -50.9%
- LIPOCINE INC NEW-$796.5K -79.8%
New Positions
- MIRUM PHARMACEUTICALS INC$12.9M
- VERADERMICS INC$9.8M
- EDITAS MEDICINE INC$4.3M
- SUTRO BIOPHARMA INC$3.8M
- ASCENDIS PHARMA A/S$3.2M
Exited Positions
- CG ONCOLOGY INC$97.4M
- TYRA BIOSCIENCES INC$7.5M
- TANGO THERAPEUTICS INC$6.3M
- AVALO THERAPEUTICS INC$5.4M
- MINERVA NEUROSCIENCES INC$5.4M
Seven Fleet Capital Management LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 156944100 | $102.3M | 16.88% | 1,439,393 | SH |
| 2 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $54.4M | 8.99% | 1,909,593 | SH |
| 3 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $41.2M | 6.80% | 1,318,551 | SH |
| 4 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $36.4M | 6.01% | 194,363 | SH |
| 5 | CG ONCOLOGY INC | CGON | 156944100 | $31.7M | 5.24% | 446,843 | SH |
| 6 | PHARVARIS N V | PHVS | N69605108 | $16.7M | 2.75% | 482,524 | SH |
| 7 | ABIVAX SA | ABVX | 00370M103 | $14.8M | 2.45% | 111,334 | SH |
| 8 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $14.7M | 2.42% | 289,136 | SH |
| 9 | LIQUIDIA CORPORATION | LQDA | 53635D202 | $14.5M | 2.40% | 182,103 | SH |
| 10 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $12.9M | 2.13% | 110,393 | SH |
| 11 | PHARVARIS N V | PHVS | N69605108 | $10.1M | 1.67% | 291,977 | SH |
| 12 | CYTOKINETICS INC | CYTK | 23282W605 | $10.1M | 1.66% | 118,240 | SH |
| 13 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $9.9M | 1.64% | 1,504,400 | SH |
| 14 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $8.9M | 1.47% | 47,666 | SH |
| 15 | VERADERMICS INC | MANE | 922967104 | $8.6M | 1.42% | 70,000 | SH |
| 16 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $8.6M | 1.41% | 246,606 | SH |
| 17 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $8.1M | 1.34% | 438,552 | SH |
| 18 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $7.9M | 1.31% | 117,067 | SH |
| 19 | XENCOR INC | XNCR | 98401F105 | $7.8M | 1.29% | 368,305 | SH |
| 20 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $7.8M | 1.29% | 220,126 | SH |
| 21 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $7.2M | 1.19% | 2,947,826 | SH |
| 22 | AXSOME THERAPEUTICS INC | AXSM | 05464T104 | $7.1M | 1.16% | 28,826 | SH |
| 23 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $7.0M | 1.15% | 148,647 | SH |
| 24 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $6.2M | 1.03% | 226,415 | SH |
| 25 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $6.1M | 1.01% | 332,213 | SH |
| 26 | LIQUIDIA CORPORATION | LQDA | 53635D202 | $5.9M | 0.98% | 74,500 | SH |
| 27 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $5.7M | 0.94% | 147,510 | SH |
| 28 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $5.7M | 0.94% | 206,732 | SH |
| 29 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $5.6M | 0.92% | 45,400 | SH |
| 30 | EDITAS MEDICINE INC | EDIT | 28106W103 | $4.3M | 0.71% | 1,330,500 | SH |
| 31 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $4.3M | 0.70% | 43,672 | SH |
| 32 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $4.2M | 0.69% | 754,397 | SH |
| 33 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $4.0M | 0.66% | 154,430 | SH |
| 34 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $3.9M | 0.64% | 76,250 | SH |
| 35 | ERASCA INC | ERAS | 29479A108 | $3.9M | 0.64% | 210,346 | SH |
| 36 | SUTRO BIOPHARMA INC | STRO | 869367201 | $3.8M | 0.63% | 159,118 | SH |
| 37 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $3.4M | 0.57% | 1,400,000 | SH |
| 38 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $3.4M | 0.56% | 130,000 | SH |
| 39 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $3.3M | 0.55% | 178,222 | SH |
| 40 | ASCENDIS PHARMA A/S | ASND | K08588103 | $3.2M | 0.52% | 11,869 | SH |
| 41 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $3.1M | 0.51% | 403,545 | SH |
| 42 | ZAI LAB LTD | ZLAB | 98887Q104 | $2.9M | 0.48% | 136,016 | SH |
| 43 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $2.7M | 0.44% | 714,000 | SH |
| 44 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $2.7M | 0.44% | 4,973 | SH |
| 45 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $2.6M | 0.43% | 70,164 | SH |
| 46 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $2.5M | 0.42% | 7,540 | SH |
| 47 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $2.4M | 0.40% | 348,265 | SH |
| 48 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $2.2M | 0.37% | 334,785 | SH |
| 49 | AGIOS PHARMACEUTICALS INC | AGIO | 00847X104 | $2.1M | 0.35% | 56,900 | SH |
| 50 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $2.1M | 0.34% | 33,300 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-17 | $605.9M | 114 | 0001013594-26-000921 |
| 2026-03-31 | 2026-06-04 | $318.3M | 115 | 0001013594-26-000652 |
| 2026-03-31 | 2026-05-15 | $315.1M | 114 | 0001013594-26-000616 |
| 2025-12-31 | 2026-04-02 | $147.8M | 87 | 0001013594-26-000420 |
| 2025-12-31 | 2026-02-26 | $131.5M | 87 | 0001013594-26-000305 |
MOUNTAIN VIEW, CA 94043